Objective:To explore the clinical application value of detection of antinuclear antibodies (ANA) spectrum eighteen
items in the diagnosis and treatment of systemic lupus erythematosus (SLE).Methods:Three hundred seventy inpatients admitted in the
rheumatology department of our hospital fromFebruary 2011 to December 2012 were selected, including SLE patients (158 cases), other
autoimmune diseases patients (142 cases) and other diseases patients (70 cases). The ANA spectrum eighteen items were detected with
indirect immunoflurescence and immunoblotting methods. The results of ANA spectrum were retrospectively analyzed.Results:The
positive rate of ten antibodies of ANA spectrum eighteen items showed significant defference between SLE group, other autoimmune
diseases group and other disease group, including ANA (96.84%, 55.47%, 27.10%, P<0.01), Anti-SSA/Ro60 (55.06%, 14.34%, 3.39%,
P<0.01), Anti-SSA/Ro52 (46.20%, 12.83%, 1.69%, P<0.01), Anti-SmD1 (31.65%, 2.64%, 1.69%, P<0.01), Anti- U1-snRNP (25.95%,
2.26%, 0%, P<0.01), AnuA(25.32%, 0.75%, 0%, P<0.01), Anti- SSB/La(25.32%, 5.66%, 0.85%, P<0.01), Anti-dsDNA(24.05%, 0.38%,
0%, P<0.01), AHA(20.89%, 0.38%, 0%, P<0.01), and Anti-P0(18.35%, 0.38%, 0%, P<0.01). The positive ANA were detected in 96.84%
SLE patients and mainly with particle type (51.63%). Two or more antibodies were detected positive in 81.65%SLE patients at the same
time.Conclusion:The detection of ANA spectrumeighteen items was valuable for the screening and diagosis of SLE. |